Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-04-21
DOI
10.1038/srep09956
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
- (2015) Anne Y. Saiki et al. Oncotarget
- Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma
- (2014) Katrin Höland et al. PLoS One
- Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy
- (2014) S Daniele et al. Cell Death & Disease
- Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma
- (2014) Simona Daniele et al. Scientific Reports
- KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis
- (2014) Seon Rang Woo et al. Biomed Research International
- mTOR signaling and its roles in normal and abnormal brain development
- (2014) Nobuyuki Takei et al. Frontiers in Molecular Neuroscience
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme
- (2013) Der-Yang Cho et al. CELL TRANSPLANTATION
- Efficacy of rapamycin against glioblastoma cancer stem cells
- (2013) M. Mendiburu-Eliçabe et al. Clinical & Translational Oncology
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
- (2013) Meenakshi Hegde et al. MOLECULAR THERAPY
- Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
- (2013) Barbara Costa et al. PLoS One
- Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
- (2013) Bryant England et al. TUMOR BIOLOGY
- Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer
- (2013) Giulia Nesi et al. ACS Medicinal Chemistry Letters
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
- (2012) Isabelle Ray-Coquard et al. LANCET ONCOLOGY
- Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
- (2012) Hernan Carol et al. PEDIATRIC BLOOD & CANCER
- Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer
- (2012) Chad M. Barnett PHARMACOTHERAPY
- Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity
- (2011) Wenzhuo Zhuang et al. INTERNATIONAL JOURNAL OF CANCER
- Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme
- (2011) Ruth Villalonga-Planells et al. PLoS One
- MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis
- (2011) Atsushi Sato et al. STEM CELLS
- The therapeutic promise of the cancer stem cell concept
- (2010) Natasha Y. Frank et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators
- (2010) Isabel Gomez-Monterrey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells
- (2010) Jun Sunayama et al. NEURO-ONCOLOGY
- Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
- (2010) Jun Sunayama et al. STEM CELLS
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
- (2009) RuiRong Yuan et al. Journal of Hematology & Oncology
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
- (2008) K Kojima et al. LEUKEMIA
- Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells
- (2008) T Maimets et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More